Spots Global Cancer Trial Database for malignant melanoma stage iv
Every month we try and update this database with for malignant melanoma stage iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma | NCT01676779 | Malignant Melan... Malignant Melan... | Dendritic cell ... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) | NCT03493230 | Malignant Melan... Malignant Melan... | quantification ... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain | NCT02439411 | Malignant Melan... Malignant Melan... | Trametinib | 18 Years - | Grupo Español Multidisciplinar de Melanoma | |
| Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | NCT03166397 | Malignant Melan... | Fludarabine Cyclophosphamid... TIL IL-2 Nivolumab Ipilimumab FMT Protocol | 18 Years - 80 Years | Sheba Medical Center | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients | NCT00722098 | Malignant Melan... | DC Vaccine & Cy... DC Vaccine & Pl... | 21 Years - 75 Years | Baylor Research Institute | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | NCT01189383 | Malignant Melan... Malignant Melan... | IL15-DC Vaccine | 21 Years - 75 Years | Baylor Research Institute | |
| Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) | NCT03493230 | Malignant Melan... Malignant Melan... | quantification ... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| The IRMI-FMT Trial | NCT04577729 | Fecal Microbiot... Malignant Melan... Malignant Melan... | Allogenic Fecal... Autologous Feca... | 18 Years - | Medical University of Graz | |
| Combined Modality Treatment for Patients With Stage IV Melanoma | NCT00313235 | Malignant Melan... | DC Vaccine and ... | 21 Years - 75 Years | Baylor Research Institute | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| The IRMI-FMT Trial | NCT04577729 | Fecal Microbiot... Malignant Melan... Malignant Melan... | Allogenic Fecal... Autologous Feca... | 18 Years - | Medical University of Graz | |
| Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain | NCT02439411 | Malignant Melan... Malignant Melan... | Trametinib | 18 Years - | Grupo Español Multidisciplinar de Melanoma | |
| Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients | NCT00722098 | Malignant Melan... | DC Vaccine & Cy... DC Vaccine & Pl... | 21 Years - 75 Years | Baylor Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
